NCT06346301 Imagery Rescripting as a Stand-alone Treatment for OCD and BDD.
| NCT ID | NCT06346301 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Condition | Obsessive-Compulsive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2023-04-21 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 36 participants in total. It began in 2023-04-21 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this multiple baseline case series study is to test the effect of imagery rescripting (ImRs) in Obsessive Compulsive Disorder (OCD) and Body Dysmorphic Disorder (BDD). Primary objective :The course of schema or core beliefs and change in OCD and BDD. To investigate the effectiveness of imagery rescripting on factors presumed to underlie the disorder, according to schema theory, and on OCD and BDD symptoms. Secondary objective: The change in OCD and BDD symptoms (full questionnaire), schemata and modes, core emotions, mood, affect and obtrusiveness of intrusion. Other objectives are research into the working mechanisms of imagery rescripting by collecting qualitative data from patients and their practitioner in a qualitative interview. For this study, a multiple-baseline single-case experimental design (SCED) is used testing different outcome variables in 18 OCD patients and 18 BDD patients. After a variable baseline period of 3-8 weeks participants will start twice weekly with imagery rescripting for 12 sessions, followed by a 6 week follow up. Participants will rate schema- or core beliefs and OCD or BDD severity on a visual analogue scale. In addition participants will rate core emotions, affect and obtrusiveness of the intrusion. Secondary we will asses four times questionnaires about OCD of BDD symptoms, depression and schemas en modes. After treatment participants will be interviewed about their experiences.
Eligibility Criteria
Inclusion Criteria: * Meet the criteria for OCD or BDD, a primary diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) * Are aged 18 and beyond * Dutch literacy * Cut-off Y-BOCS of 20 * No change in medication. Stable dose at least 6 weeks prior to study. Exclusion Criteria: * Current (hypo)mania * Active suicidal plans * Current psychosis (excluding delusional symptoms related to disorder) * Alcohol or drugs abuse as diagnosed by Diagnostic and Statistical Manual of Mental Disorders (DSM-5) * Electroconvulsive therapy in last 6 months * Neurological disorder or Intelligence Quotient \< 80
Contact & Investigator
Damiaan Denys, Prof.
PRINCIPAL INVESTIGATOR
Amsterdam UMC
Frequently Asked Questions
Who can join the NCT06346301 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Obsessive-Compulsive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06346301 currently recruiting?
Yes, NCT06346301 is actively recruiting participants. Contact the research team at t.r.vanverseveld@amsterdamumc.nl for enrollment information.
Where is the NCT06346301 trial being conducted?
This trial is being conducted at Amsterdam-Zuidoost, Netherlands.
Who is sponsoring the NCT06346301 clinical trial?
NCT06346301 is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). The principal investigator is Damiaan Denys, Prof. at Amsterdam UMC. The trial plans to enroll 36 participants.